Abstract:Background: Endogenous insulin supplementation is essential for individuals with type 1 diabetes (T1D). However, current treatments, including pancreas transplantation, insulin injections, and oral medications, have significant limitations. The development of engineered cells that can secrete endogenous insulin offers a promising new therapeutic strategy for type 1 diabetes (T1D). This approach could potentially circumvent autoimmune responses associated with the transplantation of differentiated β-cells or systemic delivery of viral vectors. Methods: We utilized CRISPR/Cas9 gene editing coupled with homology-directed repair (HDR) to precisely integrate a promoter-free EMCVIRES-insulin cassette into the 3' untranslated region (UTR) of the GAPDH gene in human HEK-293T cells. Subsequently quantified insulin expression levels in these engineered cells, the viability and functionality of the engineered cells when seeded on different cell vectors (GelMA and Cytopore I) were also assessed. Finally, we investigated the therapeutic potential of EMCVIRES-based insulin secretion circuits in reversing Hyperglycaemia in T1D mice. Result: Our results demonstrate that HDR-mediated gene editing successfully integrated the IRES-insulin loop into the genome of HEK-293T cells, a non-endocrine cell line, enabling the expression of human-derived insulin. Furthermore, Cytopore I microcarriers facilitated cell attachment and proliferation during in vitro culture and enhanced cell survival post-transplantation. Transplantation of these cell-laden microcarriers into mice led to the development of a stable, fat-encapsulated structure. This structure exhibited the expression of the platelet-endothelial cell adhesion molecule CD31, and no significant immune rejection was observed throughout the experiment. Diabetic mice that received the cell carriers reversed hyperglycemia, and blood glucose fluctuations under simulated feeding stimuli were very similar to those of healthy mice. Conclusion: In summary, our study demonstrates that Cytopore I microcarriers are biocompatible and promote long-term cell survival in vivo. The promoter-free EMCVIRES-insulin loop enables non-endocrine cells to secrete mature insulin, leading to a rapid reduction in glucose levels. We have presented a novel promoter-free genetic engineering strategy for insulin secretion and proposed an efficient cell transplantation method. Our findings suggest the potential to expand the range of cell sources available for the treatment of diabetes, offering new avenues for therapeutic interventions.

Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control

Ultrafast Glucose-Responsive, High Loading Capacity Erythrocyte to Self-Regulate the Release of Insulin

A glucose-blue light AND gate-controlled chemi-optogenetic cell-implanted therapy for treating type-1 diabetes in mice

A Self-Powered Optogenetic System for Implantable Blood Glucose Control

Antidiabetic Close Loop Based on Wearable DNA-Hydrogel Glucometer and Implantable Optogenetic Cells

Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia

The Reversal of Hyperglycaemia in Diabetic Mice Using Plga Scaffolds Seeded with Islet-Like Cells Derived from Human Embryonic Stem Cells

Glucose-activated switch regulating insulin analogue secretion enables long-term precise glucose control in type 1 diabetes mice

Designing a Retrievable and Scalable Cell Encapsulation Device for Potential Treatment of Type 1 Diabetes.

Regulation of Blood Glucose Using Islets Encapsulated in a Melanin-Modified Immune-Shielding Hydrogel

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

Tether-free Optogenetic Control of Insulin Secretion Using an Upconversion Nanoparticle-Doped Hydrogel Platform.

Erythrocyte-mimicking subcutaneous platform with a laser-controlled treatment against diabetes

Genetically Encoded Synthetic Beta Cells for Insulin Biosynthesis and Release under Hyperglycemic Conditions

Islet cell spheroids produced by a thermally sensitive scaffold: a new diabetes treatment

Pancreatic islet cells in microfluidic-spun hydrogel microfibers for the treatment of diabetes

Adipocyte-derived stem cell-based gene therapy upon adipogenic differentiation on microcarriers attenuates type 1 diabetes in mice

Optogenetic therapeutic strategies for diabetes mellitus

Enhancing Therapeutic Insulin Transport from Macroencapsulated Islets Using Sub-Minute Pressure at Physiological Levels

Week-long Normoglycaemia in Diabetic Mice and Minipigs Via a Subcutaneous Dose of a Glucose-Responsive Insulin Complex

A bio-inspired injectable hydrogel as a cell platform for real-time glycaemic regulation.